Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZYXI 
Zynex Inc (ZYXI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ZYXI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.02M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 3 | Beta 0.82 | 52 Weeks Range 1.66 - 10.62 | Updated Date 06/30/2025 |
52 Weeks Range 1.66 - 10.62 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.3% | Operating Margin (TTM) -49.28% |
Management Effectiveness
Return on Assets (TTM) -4.11% | Return on Equity (TTM) -27.52% |
Valuation
Trailing PE - | Forward PE 16.61 | Enterprise Value 127204304 | Price to Sales(TTM) 0.45 |
Enterprise Value 127204304 | Price to Sales(TTM) 0.45 | ||
Enterprise Value to Revenue 0.73 | Enterprise Value to EBITDA 20.66 | Shares Outstanding 30238900 | Shares Floating 15644385 |
Shares Outstanding 30238900 | Shares Floating 15644385 | ||
Percent Insiders 48.37 | Percent Institutions 22.21 |
Analyst Ratings
Rating 2 | Target Price 6 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zynex Inc
Company Overview
History and Background
Zynex Inc. was founded in 1996. Initially focused on developing medical devices for pain management, it has evolved to specialize in non-narcotic pain relief solutions and neurological diagnostics.
Core Business Areas
- Pain Management Devices: Designs, manufactures, and markets electrotherapy medical devices used for pain relief. This includes devices like the NeuroMove, NeuroDyne, and E-Wave.
- Neurological Diagnostics: Offers products for EMG (electromyography) and EEG (electroencephalography) testing to diagnose neurological conditions.
- Rehab: Zynex has products focused on helping those in rehab.
Leadership and Structure
Thomas Sandgaard is the Chairman, President and CEO. The company operates with a functional organizational structure, encompassing departments for R&D, manufacturing, sales, marketing, and administration.
Top Products and Market Share
Key Offerings
- Description: Used for patients who have partial paralysis
- NeuroMove: A device for stroke rehabilitation. Market share data specific to NeuroMove is not readily available; Zynex generally competes with companies like Bioness and Ottobock in the rehabilitation device market.
- Description: Used for patients who have musculoskeletal pain
- NeuroDyne: An electrotherapy device targeting muscle re-education and pain management. Competitors include DJO Global and BioMedical Life Systems. Market share data specific to NeuroDyne is not readily available
- Description: An electrotherapy device targeting muscle re-education and pain management. Competitors include DJO Global and BioMedical Life Systems. Market share data specific to E-Wave is not readily available
- E-Wave: Designed for pain relief, uses different frequencies to provide pain relief
Market Dynamics
Industry Overview
The pain management device market is growing, driven by an aging population and the opioid crisis. The neurological diagnostics market is also expanding due to increasing prevalence of neurological disorders.
Positioning
Zynex is positioned as a provider of non-narcotic pain management solutions, competing with larger companies and focusing on innovation and customer service.
Total Addressable Market (TAM)
The global pain management devices market is projected to reach tens of billions of USD. Zynex's positioning allows it to capture a share of this expanding market by focusing on specific therapeutic segments and solutions.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Direct sales force
- Strong focus on non-narcotic pain relief
- FDA approved devices
Weaknesses
- Reliance on direct sales model
- Limited international presence
- Small market capitalization compared to competitors
- Past legal issues
Opportunities
- Expanding product lines
- Acquisition Opportunities
- Strategic partnerships
- Increase telemedicine
- Increasing market acceptance of non-narcotic pain management
Threats
- Intense competition
- Changes in healthcare regulations
- Product liability claims
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BLL
- OMCL
- HALO
Competitive Landscape
Zynex's advantages include its specialized focus on non-narcotic pain management and its direct sales force. Disadvantages include its smaller size compared to competitors and limited international presence. HALO has a much bigger market share than ZyXI.
Growth Trajectory and Initiatives
Historical Growth: Zynex has experienced periods of rapid growth followed by periods of stagnation or decline, reflecting the cyclical nature of the healthcare industry and company-specific challenges.
Future Projections: Analyst estimates suggest moderate growth in revenue and earnings, driven by new product launches and expanding market share. Projections are highly dependent on product adoption rates and competitive pressures.
Recent Initiatives: Recent initiatives include expanding the product portfolio with new electrotherapy devices and diagnostic tools, focusing on sales force training, and exploring strategic partnerships.
Summary
Zynex Inc. is a company focused on pain management solutions and neurological diagnostics with some financial and reputational challenges. While the company is growing their offerings in the market, there have been instances where sales have fallen short of guidance. Overall, it is imperative that ZYXI maintains compliance with all regulations, and grows sales but cutting costs where needed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), Press releases, Analyst reports, Market research reports, Company Website, TradingView
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zynex Inc
Exchange NASDAQ | Headquaters Englewood, CO, United States | ||
IPO Launch date 2002-12-31 | Founder, President, CEO & Chairman Mr. Thomas Sandgaard | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1000 | Website https://www.zynex.com |
Full time employees 1000 | Website https://www.zynex.com | ||
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.